| Code | CSB-RA004935MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to IT-1208, targeting the CD4 glycoprotein expressed on the surface of T helper cells, regulatory T cells, monocytes, macrophages, and dendritic cells. CD4 serves as a critical co-receptor for major histocompatibility complex class II molecules and plays an essential role in adaptive immune responses by facilitating T cell receptor signaling and immune cell activation. The CD4 molecule is also notably exploited as the primary receptor for HIV-1 entry into host cells. Dysregulation of CD4-positive cell populations is associated with various autoimmune disorders, immunodeficiency states, transplant rejection, and hematological malignancies including T cell lymphomas.
IT-1208 (tregalizumab) represents a humanized IgG1 monoclonal antibody that binds to a distinct epitope on CD4 without depleting T cells, originally developed for investigating immune modulation in autoimmune conditions and transplantation settings. This biosimilar antibody provides researchers with a valuable tool for studying CD4-mediated immune regulation, T cell biology, HIV pathogenesis, and immunotherapeutic mechanisms in preclinical models.
There are currently no reviews for this product.